Pomalidomide
Back to searchMolecule Structure
Scientific Name
Pomalidomide
Description of the Drug
Pomalidomide is a thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08910
http://www.drugbank.ca/drugs/DB08910
Brand Name(s)
Imnovid, Pomalyst
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Celgene Corp, Eugia Pharma Specialities Ltd, Mylan Pharmaceuticals Inc A Viatris Co, Breckenridge Pharmaceutical Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| CRL4(CRBN) E3 ubiquitin ligase | PROTEIN COMPLEX | INHIBITOR | CHEMBL3833061 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL369172 | SCHEMBL19250920 |
| Human Metabolome Database | HMDB0256694 | |
| DrugBank | DB08910 | |
| PubChem: Thomson Pharma | 14848461 | |
| PubChem | 134780 | |
| LINCS | LSM-45637 | |
| Nikkaji | J1.121.690K | |
| BindingDB | 65456 | |
| EPA CompTox Dashboard | DTXSID40893458 | |
| DrugCentral | 4746 | |
| ChemicalBook | CB32128749 | |
| Guide to Pharmacology | 7348 | |
| rxnorm | POMALYST | POMALIDOMIDE |
| PubChem: Drugs of the Future | 50086901 | |
| ChEBI | 72690 |
